# A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Source: https://onco.cc/trials/nct05335993/  
OnCo record `nct05335993` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Oregovomab, Niraparib in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.

## Summary

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT05335993 by CanariaBio Inc., with 10 participants enrolled, started 2022-07-25 and due to reach its primary completion in 2026-12-30. Interventions recorded: Oregovomab, Niraparib. Conditions listed: Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05335993
- Phase: 2
- Setting: Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
- Sponsor: CanariaBio Inc.
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT05335993: https://clinicaltrials.gov/study/NCT05335993

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Niraparib](https://onco.cc/drugs/niraparib/), [Oregovomab](https://onco.cc/drugs/oregovomab/)

---
JSON: https://onco.cc/api/v1/entities/nct05335993.json